Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 5/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690189 | 0.78 | NQO2 (0.53) | ALDH1A1IMPDH2KDM4EERN1HTR1D | |
| SCHEMBL1093104 | 0.78 | ALDH1A1 (0.51) | ALDH1A1IMPDH2KDM4EERN1TDP1 | |
| SCHEMBL19865517 | 0.73 | NQO2 (0.42) | ALDH1A1KDM4EMAPTRAB9ANQO2 | |
| SCHEMBL31205479 | 0.73 | ALDH1A1 (0.46) | ALDH1A1IMPDH2KDM4EERN1HTR1D | |
| SCHEMBL8818184 | 0.72 | ALDH1A1 (0.41) | ALDH1A1KDM4EERN1TSHRNPC1 | |
| SCHEMBL30045931 | 0.72 | ALDH1A1 (0.41) | ALDH1A1KDM4EERN1TSHRNPC1 | |
| SCHEMBL1451216 | 0.71 | ALDH1A1 (0.57) | ALDH1A1IMPDH2KDM4EERN1TDP1 | |
| SCHEMBL27756846 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KDM4EERN1TDP1TSHR | |
| SCHEMBL1138275 | 0.67 | PTGER3 (0.55) | ALDH1A1IMPDH2 | |
| SCHEMBL1043732 | 0.66 | ERN1 (0.61) | ALDH1A1KDM4EERN1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018031662-A1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20040176332-A1 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| US-6656926-B2 | For therapy and prophylaxis of cancer | PURDUE RESEARCH FOUNDATION | 2003-12-02 | — | — | US | disclosed |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176332-A1 | Phosphoramide compounds | RB1, RRM2B, RRM1 | ALDH1A1 1067/4885IMPDH2 892/4885KDM4E 3140/4885 |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | BRCA1, RRM2B, FOLR1 | ALDH1A1 27/4885IMPDH2 1436/4885KDM4E 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.